News & Events zu Lifecore Biomedical Inc (LFCR)LFCRLifecore Biomedical Inc

Lifecore Biomedical Trading Halted, News Pending

Lifecore Biomedical trading halted, news pending

Lifecore Biomedical Acquired by Webster Equity Partners in $663.7M Deal

Lifecore Biomedical announced that it has entered into a definitive agreement to be acquired by Webster Equity Partners in a transaction valued at up to $663.7M, assuming full achievement of certain performance milestones. Under the terms of the agreement, an entity affiliated with Webster Equity Partners will acquire all outstanding Lifecore common stock for $6.28 per share in cash at closing plus one non-tradable contingent value right per share. The holders of the Lifecore Series A Preferred Stock will be entitled to a payment in cash at closing equal to the "Conversion Amount" as defined in the Certificate of Designations relating to the Series A Preferred Stock as of the closing date, plus one non-tradable CVR per share of common stock into which the Series A Preferred Stock is convertible as of closing. The initial cash consideration of $6.28 per share of common stock represents a premium of approximately 49.5% to Lifecore's closing price on September 25, 2026, the last full trading day prior to signing the merger agreement. Assuming full CVR performance milestone payments of $160 million, the aggregate potential merger consideration of $9.67 per share of common stock or common stock equivalent represents a premium of approximately 130.2% to Lifecore's closing price on September 25, 2026, the last full trading day prior to signing the merger agreement.